Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections.

来自 EBSCO

阅读量：

作者：

E Attanasio，P Russo，G Carunchio，A Basoli，L Caprino

展开

摘要：

Background: The efficacy of two carbapenems, imipenem/cilastatin (I/C, 1.5 g daily) versus meropenem (3 g daily) in intra-abdominal infections was assessed in a recent multicenter randomized clinical trial. The aim of this article is to perform a cost-effectiveness analysis as in real-world practice according to the findings of this clinical trial. Methods: A decision tree was used to estimate the clinical outcomes and direct costs of treating intra-abdominal infections using the two carbapenems from the perspective of the Italian National Health Service (INHS) or a private insurance company (PIC). Results: In a population of 30,000 patients with intra-abdominal infections in Italy, it was estimated that 97 potential deaths/year could be avoided if these patients were treated with I/C versus meropenem. In addition, from the perspective of INHS, the total costs of treatment were estimated as ITL 106,874 million and 134,042 million for I/C and meropenem, respectively. In favor of the PIC point of view, the total costs were estimated as ITL 110,500 million and 135,899 million for I/C and meropenem, respectively. Conclusion: The treatment of intra-abdominal infections with I/C is shown to be more effective (97 deaths avoided/year) and less costly than with meropenem (with a saving of ITL 27,168 and 25,399 million/year for INHS and PIC, respectively).Copyright u00a9 2000 S. Karger AG, Basel

展开

关键词：

Cost-effectiveness Imipenem/cilastatin Meropenem Intra-abdominal infection

DOI：

10.1159/000018822

被引量：

年份：

2000